These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 33052222)

  • 1. First clinical study of a pegylated diabody
    Scott AM; Akhurst T; Lee FT; Ciprotti M; Davis ID; Weickhardt AJ; Gan HK; Hicks RJ; Lee ST; Kocovski P; Guo N; Oh M; Mileshkin L; Williams S; Murphy D; Pathmaraj K; O'Keefe GJ; Gong SJ; Pedersen JS; Scott FE; Wheatcroft MP; Hudson PJ
    Theranostics; 2020; 10(25):11404-11415. PubMed ID: 33052222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody.
    Zettlitz KA; Tsai WK; Knowles SM; Kobayashi N; Donahue TR; Reiter RE; Wu AM
    J Nucl Med; 2018 Sep; 59(9):1398-1405. PubMed ID: 29602820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monodispersed DOTA-PEG-conjugated anti-TAG-72 diabody has low kidney uptake and high tumor-to-blood ratios resulting in improved 64Cu PET.
    Li L; Turatti F; Crow D; Bading JR; Anderson AL; Poku E; Yazaki PJ; Williams LE; Tamvakis D; Sanders P; Leong D; Raubitschek A; Hudson PJ; Colcher D; Shively JE
    J Nucl Med; 2010 Jul; 51(7):1139-46. PubMed ID: 20554731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improved 64-copper PET imaging.
    Li L; Crow D; Turatti F; Bading JR; Anderson AL; Poku E; Yazaki PJ; Carmichael J; Leong D; Wheatcroft D; Raubitschek AA; Hudson PJ; Colcher D; Shively JE
    Bioconjug Chem; 2011 Apr; 22(4):709-16. PubMed ID: 21395337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.
    Sundaresan G; Yazaki PJ; Shively JE; Finn RD; Larson SM; Raubitschek AA; Williams LE; Chatziioannou AF; Gambhir SS; Wu AM
    J Nucl Med; 2003 Dec; 44(12):1962-9. PubMed ID: 14660722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of a
    Jadvar H; Chen K; Park R; Yap LP; Vorobyova I; Swenson S; Markland FS
    Amino Acids; 2019 Nov; 51(10-12):1569-1575. PubMed ID: 31621030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas.
    Pishvaian M; Morse MA; McDevitt J; Norton JD; Ren S; Robbie GJ; Ryan PC; Soukharev S; Bao H; Denlinger CS
    Clin Colorectal Cancer; 2016 Dec; 15(4):345-351. PubMed ID: 27591895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results.
    Zou P; Povoski SP; Hall NC; Carlton MM; Hinkle GH; Xu RX; Mojzisik CM; Johnson MA; Knopp MV; Martin EW; Sun D
    World J Surg Oncol; 2010 Aug; 8():65. PubMed ID: 20691066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor uptake of pegylated diabodies: Balancing systemic clearance and vascular transport.
    Li Q; White JB; Peterson NC; Rickert KW; Lloyd CO; Allen KL; Rosenthal K; Gao X; Wu H; Dall'Acqua WF; Borrok MJ; Tsui P
    J Control Release; 2018 Jun; 279():126-135. PubMed ID: 29653224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
    Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
    Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo evaluation of PEGylated ⁶⁴Cu-liposomes with theranostic and radiotherapeutic potential using micro PET/CT.
    Petersen AL; Henriksen JR; Binderup T; Elema DR; Rasmussen PH; Hag AM; Kjær A; Andresen TL
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):941-952. PubMed ID: 26646780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody.
    Li L; Yazaki PJ; Anderson AL; Crow D; Colcher D; Wu AM; Williams LE; Wong JY; Raubitschek A; Shively JE
    Bioconjug Chem; 2006; 17(1):68-76. PubMed ID: 16417253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody.
    Cai W; Olafsen T; Zhang X; Cao Q; Gambhir SS; Williams LE; Wu AM; Chen X
    J Nucl Med; 2007 Feb; 48(2):304-10. PubMed ID: 17268029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
    Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
    J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
    Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
    J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET Imaging of VCAM-1 Expression and Monitoring Therapy Response in Tumor with a
    Zhang X; Liu C; Hu F; Zhang Y; Wang J; Gao Y; Jiang Y; Zhang Y; Lan X
    Mol Pharm; 2018 Feb; 15(2):609-618. PubMed ID: 29308904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.
    Weber T; Bötticher B; Arndt MA; Mier W; Sauter M; Exner E; Keller A; Krämer S; Leotta K; Wischnjow A; Grosse-Hovest L; Strumberg D; Jäger D; Gröne HJ; Haberkorn U; Brem G; Krauss J
    Cancer Lett; 2016 Oct; 381(2):296-304. PubMed ID: 27524505
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.